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Abstract
Purpose Anti-Mullerian hormone (AMH) is commonly
known as the most potent marker for ovarian reserve due to
its decline as female age increases. While serum AMH
(sAMH) levels have been intensively investigated, there is
less data regarding AMH concentrations in follicular fluid
(FF), since FF has usually been designated as waste product
during oocyte collection in assisted reproductive technologies.
This pilot study investigated follicle AMH concentrations
(fAMH) of several follicles per ovary, individually collected
with the Steiner-Tan needle, and compared them to sAMH
concentrations in women undergoing IVF treatment. We hy-
pothesized that there is no difference of fAMH concentrations
in individual follicles and that these concentrations resemble
the sAMH value of the patient.
Methods Patients were stimulated with a gonadotropin-
releasing hormone antagonist ovarian hyperstimulation proto-
col. On the day of oocyte retrieval, serum samples and FF
from all individual follicles from one stimulated IVF cycle
were collected and individually analyzed for AMH
concentrations.
Results Intracyclic mean fAMH values (nfollicle = 2–14) were
significantly correlated to sAHM values (ρ = 0.85, p < 0.001)
and showed a trend to be negatively associated with age
(ρ = −0.43, p = 0.06). Mean intrapatient fAMH concentrations
differed significantly (p < 0.001). Furthermore, significant
correlations of sAMH with individual fAMH values of the
first five follicles of each patient were observed.
Conclusions In conclusion, our results clearly showed that
individual fAMH concentrations reflected sAMH values and
that fAMH concentrations did not significantly differ within
one patient. In future studies, it will be interesting to correlate
individual fAMH values to the respective embryo develop-
ment and overall pregnancy outcome in order to improve
IVF treatments and to refrain from embryo overproduction.
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Introduction
Follicular fluid (FF) is a mixture of chemical constituents,
comprising a variety of different proteins as well as growth
factors, reactive oxygen species, anti-apoptotic factors, fatty
acids, sugars, and hormones [1]. Among them, the Anti-
Mullerian hormone (AMH), a homodimeric glycoprotein
which belongs to the transforming growth factor-β (TGF-β)
family, has evolved to become one of the most prominent
targets for reproductive health research [2]. Anti-Mullerian
hormone is secreted primarily by granulosa cells of ovarian
follicles during early stages of follicle development (pre-antral
and antral follicles) [3] but has also been found in endometrial
and endometriotic tissue [4]. Females are born with a defined
number of primordial follicles, whose quantity and quality
define the ovarian reserve [5]. Oocytes within primordial fol-
licle rest in a dormant state of meiosis I until puberty, and until
then, the granulosa cells do not secrete AMH. A recent study
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demonstrated the beginning of AMH secretion with the re-
cruitment of the follicles [6], with maximum AMH values at
the age of 15.8 years. After a plateau phase until the age of
25 years, AMH concentrations start to decrease and inversely
correlate with age. This emphasizes AMH as the most potent
marker for ovarian reserve in women of 25 years and older [7]
among other parameters commonly used such as antral follicle
count, follicle stimulating hormone (FSH), luteinizing hor-
mone (LH), estradiol, or inhibin B. During the menstrual cycle
serum AMH (sAMH), values remain relatively stable com-
pared to all other hormones secreted by the ovary and can be
analyzed at any day of the cycle, which is an advantage for
flexible in vitro fertilization (IVF) treatment [8].
Values of sAMH have been intensively investigated [9,
10]; however, there is less data regarding the behavior of
AMH concentrations in FF (fAMH), since FF has usually
been designated as waste product during oocyte collection
for IVF treatment. Recent studies revealed the importance of
FF in oocyte development [11], providing information on fol-
licular growth, oocyte quality, and fertilization. However, in
studies to date, FFs have either been pooled [12] or solely the
dominant follicle was examined [13]. Information on individ-
ual fAMH concentrations within one stimulated IVF cycle is
still not available, although it is tempting to speculate that
individual fAMH could be a potential predictor of fertilization
success in IVF treatments, since it had already been found to
correlate with the respective embryo and IVF outcome, at least
regarding the FF of the dominant follicle [14]. Due to different
study designs and methods used (dominant or pooled follicle
analysis), it is hardly possible to compare results and draw any
conclusions. Comparing all individual fAMH values with the
respective embryo and IVF outcome, however, has not yet
been done and would emphasize fAMH even more as potent
biomarker in IVF treatment by facilitating and complementing
the embryo selection process.
In this pilot study, we demonstrated that all mature follicles
during a stimulated IVF cycle could be aspirated individually
with the Steiner-Tan needle [15] for fAMH analysis. We hy-
pothesized that there was no difference between fAMH con-
centrations of individual follicles within one patient and that




Blood serum (n = 17) and follicular fluid samples (n = 20) of
female volunteers, age 26–43, undergoing IVF treatment were
prospectively collected and analyzed for AMH concentrations
if they met the following criteria: (1) both ovaries present, (2)
BMI between 19 and 30, (3) adequate visualization of ovaries
in transvaginal ultrasound scan, (4) written informed consent
of the patients, and (5) stimulation with gonadotropin-
releasing hormone (GnRH) antagonist protocol. Samples
were collected at the Kinderwunsch Institut Dobl, Austria,
between 2014 and 2015. Informed consent was obtained from
each woman with approval of the ethical committee of the
Medical University of Graz (approval number 20–492
ex08/09).
Ovarian hyperstimulation protocol
All women included for the study underwent GnRH antago-
nist protocol controlled ovarian hyperstimulation. Patients re-
ceived recombinant human follicle stimulating hormone
(Puregon; MSD Sharp & Dohme GMBH) for 5 days with
doses according to age, weight, sAMH, and hormonal status
[16, 17]. Trans-vaginal sonographywas performed after 5 days
and on the day of oocyte retrieval. Ultrasonographical mea-
surement was performed using a RIC 5-9-D 4D intravaginal
probe of a GE Voluson E8 BT09 ultrasound machine (both
from GE Healthcare Austria GmbH). GnRH antagonist
(Cetrotide, Merck KGaA) was injected to avoid premature
ovulation. Triggering was initiated 35 h before the punction,
administered with 5000–10,000 IU human chorionic gonado-
tropin (hCG) subcutaneously (Pregnyl, N.V. Organon), with
dose according to body weight of the patient [16].
Oocyte and follicular fluid retrieval
Oocyte retrieval was performed under sedation (Propofol,
Fresenius Kabi Austria GmbH; Rapifen, Janssen-Cilag
Pharma GmbH). Every follicle larger than 10 mm in diameter
was aspirated and flushed (Flushing medium GM501 Flush;
Gynemed Medizinprodukte GmbH & Co.KG) under
transvaginal ultrasound guidance (GE Healthcare Austria
GmbH) with a Steiner-Tan needle 17 gauge and a Steiner
flush/valve (IVFETFLEX.com HandelsgmbH & Co KG)
[15]. Follicles closest to the vagina were aspirated first.
Follicular fluid was examined for oocytes under constant
conditions of 37 °C in an IVF workstation L24E with
heating stage (K-SYSTEMS Kivex Biotec A/S) and was
subsequently stored at 4 °C for further hormonal analysis.
The flushing volumes were examined for oocytes and
discarded afterwards. The method of collection and storage
of FF as well as other body liquids within the frame of IVF
(blood serum, cumulus cells, seminal plasma, embryo culture
supernatant) was previously described by Schenk et al. [18],
providing comprehensive information on laboratory
procedures and sampling techniques to enable the
comparability of future studies in the field of reproductive
health research.
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Blood serum collection
Blood serum was collected on day of oocyte retrieval. At least
4 ml of blood was taken by venipuncture into an 8-ml vacuette
tube with serum separator (Greiner Bio-One International
GmbH). Samples were centrifuged at 1800g for 10 min, and
serum supernatant was collected and stored at 4 °C in 15-ml
tubes (VWR International GmbH) for subsequent AMH
analysis.
Quantitative analysis of AMH
Serum and follicular fluid AMH concentrations were deter-
mined using electrochemiluminescence immunoassay
(ECLIA) for quantitative determination (Cobas-e411 analyz-
er, Roche Diagnostics GmbH). The analysis is fully automated
with a mean intra-assay coefficient of variability (CV) of
1.34% and a mean inter-assay CVof 3.84% for sAMH accord-
ing to the manufacturer’s data sheet. Follicular fluid was cen-
trifuged 10 min at 3000g before measurement. Samples were
analyzed according to the manufacturer’s instructions in a
measurement range of 0.01–23 ng/ml. For validation of par-
allelism [19] of the obtained fAMH results, samples were
diluted 1:2, 1:5, 1:10, 1:20, 1:50, and 1:100 in buffer and
reanalyzed.
Statistical analysis
Data are presented as individual or mean values. All variables
were tested for normal distribution with the Kolmogorov-
Smirnov test. Depending on variables’ distributions,
Pearson’s or Spearman’s rank correlation analysis was used
to detect associations between continuous variables. An a
priori power analysis revealed a necessary sample size of
n = 17 in order to detect any significant relationship (effect
size = 0.7, alpha = 0.05, 1-beta = 0.92). Differences between
sAMH and intra-individual fAMH values of the first five fol-
licles (median number of follicles in this patient cohort) were
investigated by repeated measures ANOVA with Bonferroni
post hoc corrections. Comparison of mean fAMH values of all
follicles between patients was done by one-way ANOVAwith




A total of 20 patients (age 35.8 ± 5.5 years; BMI 22.1 ± 2.4 kg/
m2) undergoing IVF treatment between 2014 and 2015 were
analyzed (Table 1). The number of aspirated follicles ranged
from two to 14, according to the number of follicles matured
during IVF treatment.
Inter-variable relationships
Mean fAMH values (nfollicle = 2–14) were significantly corre-
lated to sAMH values (ρ = 0.85, p < 0.001, n = 17; Fig. 1).
Younger patients showed by trend higher fAMH concentra-
tions than older ones (ρ = −0.43, p = 0.06, n = 20), while their
body mass index was not significantly associated (p > 0.05).
Table 1 Individual
patient characteristics Patients ID Age BMI nfollicle
1 35 23.0 5
2 32 22.3 3
3 43 20.8 3
4 30 20.3 14
5 26 21.6 6
6 32 21.3 10
7 35 21.7 5
8 41 24.6 3
9 39 19.4 12
10 42 30.1 7
11 41 21.3 5
12 30 19.9 13
13 43 20.8 6
14 36 20.3 12
15 31 21.6 4
16 33 21.8 6
17 41 24.2 8
18 43 21.2 4
19 28 22.9 2
20 35 20.3 5
nfollicle number of follicles collected during
IVF treatment
Fig. 1 Relationship of intracyclic mean fAMH values (nfollikel = 2–14) to
sAHM values (ρ = 0.85)
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Likewise, sAMH concentrations revealed a significant rela-
tionship to age (r = −0.53, p < 0.05, n = 17).
Furthermore, significant correlations of sAMH with indi-
vidual fAMH values of the first five follicles of each patient
were observed (r1 = 0.89, n = 17, p < 0.001; r2 = 0.81, n = 17,
p < 0.001; r3 = 0.67, n = 16, p < 0.01; r4 = 0.66, n = 14,
p < 0.05; r5 = 0.70, n = 12, p < 0.05) (Fig. 2).
Quantification of AMH concentrations in blood serum
and follicular fluid: intracyclic and intrapatient analysis
It was clearly visible that AMH could be measured in an
individual follicle, since AMH values among five different
follicles of one patient were not significantly different from
each other and comparable to sAMH values (n = 14, p > 0.05).
Quantification of AMH concentrations in blood serum
and follicular fluid: subanalyses between patients
Mean fAMH concentrations between patients differed signif-
icantly (p < 0.001, nfollicle per patient = 2–14, Fig. 3).
Discussion
In the present study, we provided evidence that fAMH con-
centrations differed between patients but not within one stim-
ulated IVF cycle and that individual fAMH values correlated
with sAMH data of the respective patient. We demonstrated
that FF can be collected from individual follicles within one
stimulated cycle (intracyclic) with the Steiner-Tan needle.
In contrast to previous studies, we measured AMH concen-
trations of all individual follicles within one stimulated IVF
cycle of patients undergoing IVF treatment and demonstrated
a significant correlation between sAMH and mean/individual
fAMHvalues within patients. This AMH data of all individual
mature follicles is unique and supports other studies, which
correlated AMH values of the first punctured follicle [20] or
pooled FF [21] with sAMH. Peripheral AMH concentrations
are exclusively dependent not only on the number of follicles
but also on the individual ability of each follicle to produce
AMH [22]. Small follicles exhibit higher AMH concentra-
tions compared to large ones, according to the fact that gran-
ulosa cells reduce their AMH production during final follicu-
lar maturation [23, 24]. Our results also revealed a significant
difference in mean fAMH concentrations between patients,
which may be based on the varying mature follicle sizes dur-
ing one stimulated cycle in IVF treatment [25]. Interestingly,
mean fAMH showed a trend to be negatively correlated with
age, which is in line with the overall AMH decrease in patients
with increasing age. Additionally, our results demonstrated
decreasing sAMH concentrations with increasing age of the
patient, thereby confirming the state-of-the-art opinion that
sAMH values inversely correlate with age [7].
In general, fAMH concentrations are positively associated
with embryo implantation when measuring the AMH concen-
trations in the dominant follicle [26]. Studies suggested that
higher fAMH values positively correlated with fertilization
[27] and implied higher chances for pregnancy [28]. On the
other hand, Mehta et al. demonstrated a negative correlation
between fAMH and oocyte quality, fertilization, pregnancy,
and embryo implantation rates [12]. A major disadvantage
of numerous studies is the diverging dataset of FF investigat-
ed. It is hardly possible to draw conclusions from pooled FF or
dominant follicle analysis only. These data provided hints but
did not reflect AMH concentrations in all-grown follicles
available with no possibility for future association of individ-
ual FF with the respective IVF outcome. Our data provided
evidence that fAMH concentrations of individual folli-
cles of one hormonal stimulated cycle during IVF treat-
ment did not significantly differ within one patient and
resembled sAMH values.
Fig. 3 Individual follicle AMH (fAMH) values in all patients (nfollicle
per patient = 2–14). Mean fAMH concentrations significantly differed
between patients (one-way ANOVA, p < 0.001)
Fig. 2 Correlation of sAMH with individual fAMH values of the first
five follicles of each patient
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A limitation of the study is that we did not investigate the
respective IVF outcome of different FF and associated embry-
os. In addition, the small sample size must be considered as a
possible drawback. Another limitation is the lack of informa-
tion on size and volume of the aspirated follicles, since corre-
lation of these parameters with the IVF outcome would lead to
a more conclusive analysis. However, volumetric analysis and
sizing of follicles are time-consuming procedures and unnec-
essarily prolong anesthesia and patient discomfort.
Conclusion
In conclusion, our results clearly showed that individual
fAMH concentrations reflected sAMH values of a stimulated
cycle during IVF treatment and that fAMH concentrations did
not significantly differ within one patient. In future studies, it
will be interesting to correlate individual fAMH values to the
respective embryo development and overall pregnancy out-
come in order to improve IVF treatments and to refrain from
embryo overproduction.
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